Abstract��OBJECTIVE To evaluate the cost-effectiveness of insulin aspart30(BIAsp 30) versus premixed human insulin 30/70 (BHI 30) in patients with type 2 diabetes (T2DM) in China so as to provide a reference for relevant decision of drug selection and drug pricing. METHODS Based on a secondary document study method and literature review both at home and abroad, a summary and screening were made on the safety and effectiveness of BIAsp 30 versus BHI 30 for the treatment among insulin-naive people with T2DM. A Meta-analysis was performed to assess the effectiveness and safety of the selected data by using software RevMan5.2. Then combine the price from the National Development and Reform Commission, National Health and Family Planning Commission to perform cost-effectiveness analysis from a social prospective. Sensitivity analysis and publication bias were conducted. RESULTS Treatment with BIAsp 30 is associated with more cost than BHI 30 (��1 665.44 vs ��1 383.86),and the effectiveness data of BIAsp 30 was higher than BHI 30 (2.46 vs 1.83). Compared with BHI 30, BIAsp 30 is more efficient in pharmacoeconomic cost-effectiveness analysis, and sensitivity analyses demonstrated robustness of the RESULTS. CONCLUSION BIAsp 30 is better than BHI 30 in terms of the economy, but it still needs further research.
��ѩ, ������. �Ŷ��ȵ���30�;���������ϳ����ȵ���30R����2�����ĳɱ�-Ч������[J]. �й�ҩѧ��־, 2016, 51(21): 1895-1900.
ZHAO Xue, SUN Li-hua. Cost-Effectiveness Analysis of Insulin Aspart30 Versus Premixed Human Insulin 30/70 in Patients with Type 2 Diabetes in China. Chinese Pharmaceutical Journal, 2016, 51(21): 1895-1900.
Chinese Diabetes Society. Guidelines for prevention and treatment of type 2 diabetes in China (2013 Edition)[J]. Chin J Diabet(�й�������־), 2014, 22(8):2-42.
Chinese Society of Endocrinology. Expert consensus ofthe clinical insulin application for Chinese adult with type 2 diabetes [J]. Chin J Endocrinol Metabol(�л��ڷ��ڴ�л��־), 2013, 29(1):1-6.
MENET. Diabetes drug market research report for 2013[EB/OL]. 2015 [2015-12-01]. http://www. menet. com. cn/vip/article/article2. aspx?id=100224.
ZHU L, LI S, FU X, et al. The clinical study to treatment of newly diagnosed type 2 diabetes with BIAsp 30 and BHI 30[J]. Sichuan Med J(�Ĵ�ҽѧ), 2010, 31(7):917-918.
SAKURABA H, MIZUKAMI H, YAGIHASHI N, et al. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type �� diabetic patients[J]. Diabetologia, 2002, 45(1):85-96.
QIAN L, XU L, FU X, et al. Early insulin secretion failure leads to diabetes in Chinese subjects with impaired glucose regulation[J]. Diabetes Metabolism Res & Rev, 2009, 25(2):144-149.
LIU G, HU S, WU J. China guidelines for pharmacoeconomic evaluations(2011 edition)[J]. China J Pharm Economics(�й�ҩ�ﾭ��ѧ), 2011,3:6-9, 11-48.
SUN L. Pharmaceutical Economics[M]. Second Edition. Beijing: China Medical Science Press, 2010.
Chinese Society of Endocrinology. Expert consensus of HbA1C control target for Chinese adult with type 2 diabetes[J]. Chin J Endocrinol Metabol(�й�ҽѧǰ����־), 2011, 27(5):371-374.
LI W. Clinical application guide of blood glucose monitoring in China (Edition 2015)[J]. Chin J Diabetes(�й�������־), 2015, 7(10):23-25.
ZHENG Y, ?STERLE A, LIU X, et al. PDB22 the direct medical cost for diabetes mellitus (DM) related complications in China[J]. Value Health, 2012, 15(7):662-663.
STRATTON I M, ADLER A I, NEIL H A, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study [J]. BM J Clinic Res, 2000, 321(7258):405-412.
ROSENQVIST U. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [J]. New England J Med, 1993, 329(14):977-986.
LEITER L A, YALE J F, CHIASSON J L, et al. Assessment of theimpact of fear of hypoglycemic episodes on glycemic andhypoglycemia management[J]. Can J Diabetes, 2005, 29(3):186-192.